Lexaria Bioscience Corp. (LEXX) saw an uptrend of 28.07% in the recent trading with $8.44 being its most recent. The current price level -34.57% lower than the highest price of $12.90 marked by the stock while trading over the past 52-weeks, whereas it is 112.32% higher than the lowest price of $3.98 the company dropped to over past 52-weeks. The latest news story on LEXX appeared in ACCESSWIRE under the title “Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3” on Jul-21-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -32.48% below one month high and is +34.82% above of the lowest during that time. Looking into the simple moving average, Lexaria Bioscience Corp. (LEXX)’s stock stands at a SMA-50 of $6.56 while that of 5-day is reading $6.95.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Lexaria Bioscience Corp. Earnings – What Happened With LEXX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $192.0 million.
LEXX – Lexaria Bioscience Corp. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 5.10 million. LEXX does have institutional investors; and they hold 7.50% of the stock.
Lexaria Bioscience Corp. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, LEXX declared 0 shares have been sold in 0 insider transactions over the past three months.
Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Lexaria Bioscience Corp. was 8.53 while posting a debt to equity ratio of 0.00. The count was 4.75 for long-term debt to equity ratio.
Lexaria Bioscience Corp.’s return on equity, or ROE, is -53.80%, compared to the industry average of -38.26% for Consumer Defensive – Packaged Foods. Although this indicates that LEXX fails to use its equity well, the metric will vary significantly depending on the industry.